Which medication combination is usually administered to patients about to undergo PCI?

Which medication combination is usually administered to patients about to undergo PCI?

• A. Digoxin + Aspirin
• B. Prasugrel + Aspirin
• C. Ticagrelor + Clopidogrel
• D. Clopidogrel + Warfarin

Answer: (B)

Prasugrel combined with aspirin is a well-established medication regimen for patients undergoing percutaneous coronary intervention (PCI). This combination works effectively to prevent thrombosis in patients who have acute coronary syndrome or are undergoing stenting. Prasugrel is a powerful antiplatelet agent that helps inhibit platelet activation and aggregation, thereby reducing the risk of heart attacks or stent-related complications during and after the procedure. When administered alongside aspirin, which also provides antiplatelet effects, the two drugs create a robust protective effect against cardiac events. This dual antiplatelet therapy is particularly crucial in the setting of PCI since the procedure carries a risk of clot formation at the site of the stent. Using both prasugrel and aspirin enhances the success of the intervention by promoting optimal coronary artery patency and reducing the likelihood of adverse cardiovascular outcomes. Other combinations listed may not provide the same level of efficacy or are not as commonly used in this specific context. For instance, digoxin is primarily used for heart failure and doesn't serve an antiplatelet function, while clopidogrel and warfarin typically address thromboembolic risk in other settings, not specifically for PCI with the same focus on immediate antiplatelet activity. Therefore

Prasugrel combined with aspirin is a well-established medication regimen for patients undergoing percutaneous coronary intervention (PCI). This combination works effectively to prevent thrombosis in patients who have acute coronary syndrome or are undergoing stenting.

Prasugrel is a powerful antiplatelet agent that helps inhibit platelet activation and aggregation, thereby reducing the risk of heart attacks or stent-related complications during and after the procedure. When administered alongside aspirin, which also provides antiplatelet effects, the two drugs create a robust protective effect against cardiac events.

This dual antiplatelet therapy is particularly crucial in the setting of PCI since the procedure carries a risk of clot formation at the site of the stent. Using both prasugrel and aspirin enhances the success of the intervention by promoting optimal coronary artery patency and reducing the likelihood of adverse cardiovascular outcomes.

Other combinations listed may not provide the same level of efficacy or are not as commonly used in this specific context. For instance, digoxin is primarily used for heart failure and doesn't serve an antiplatelet function, while clopidogrel and warfarin typically address thromboembolic risk in other settings, not specifically for PCI with the same focus on immediate antiplatelet activity. Therefore